Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone

Mafopa, Nadege Goumkwa; Russo, Gianluca; Wadoum, Raoul Emeric Guetiya; Iwerima, Emmanuel; Bátwala, Vincent; Giovanetti, Marta; Minutolo, Antonella; Turay, P; Turay, Thomas B.; Kargbo, Brima; Amicosante, Massimo; Mattei, Maurizio; Montesano, Carla

doi:10.4081/jphia.2017.732

Cited by 8 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seroprevalence studies have been used in the past to help with outbreak responses. During a recent Ebola outbreak, seroprevalence studies were performed to gain further information on the immune response and immune protection (13). Seroprevalence studies have also been used for infections such rubella, mumps and measles to map resurgence and to gain further information on how public health strategies can target high risk populations (14).…”

Section: Introductionmentioning

confidence: 99%

The Seroprevalence of SARS-CoV-2 in Europe: A Systematic Review

Vaselli

Hungerford

Shenton

et al. 2021

Preprint

View full text Add to dashboard Cite

Background A year following the onset of the COVID-19 pandemic, new infections and deaths continue to increase in Europe. Serological studies, through providing evidence of past infection, can aid understanding of the population dynamics of SARS-CoV-2 infection. Objectives This systematic review of SARS-CoV-2 seroprevalence studies in Europe was undertaken to inform public health strategies including vaccination, that aim to accelerate population immunity. Methods We searched the databases Web of Science, MEDLINE, EMBASE, SCOPUS, Cochrane Database of Systematic Reviews and grey literature sources for studies reporting seroprevalence of SARS-CoV-2 antibodies in Europe published between 01/12/2019 - 30/09/20. We provide a narrative synthesis of included studies. Studies were categorized into subgroups including healthcare workers (HCWs), community, outbreaks, pregnancy and children/school. Due to heterogeneity in other subgroups, we only performed a random effects meta-analysis of the seroprevalence amongst HCWs stratified by their country. Results 109 studies were included spanning 17 European countries, that estimated the seroprevalence of SAR-CoV2 from samples obtained between November 2019 – August 2020. A total of 53/109 studies included HCWs with a reported seroprevalence among HCWs ranging from 0.7% to 45.3%, which did not differ significantly by country. In community studies significant heterogeneity was reported in the seroprevalence among different age groups and the majority of studies reported there was no significant difference by gender. Conclusion This review demonstrates a wide heterogeneity in reported seroprevalence of SARSCoV-2 antibodies between populations. Continued evaluation of seroprevalence is required to understand the impact of public health measures and inform interventions including vaccination programmes.

show abstract

Section: Introductionmentioning

confidence: 99%

The Seroprevalence of SARS-CoV-2 in Europe: A Systematic Review

Vaselli

Hungerford

Shenton

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Also in agreement with our findings, a recent study using a MMIA specific for EBOV documented EBOV IgG antibodies in human serum samples collected in Guinea in 2012, although the first recorded case of EBOV in Guinea was not reported until the following year (December 2013) [67]. There is an increasing body of evidence that EBOV and MARV are capable of causing asymptomatic or mild infections, which may account for the detection of EBOV-and MARV-specific antibodies in the human population in the absence of a history of haemorrhagic symptoms or an outbreak of haemorrhagic disease [72][73][74]. Indeed recent studies have documented the presence of anti-EBOV antibodies in populations with no history of EBOV outbreaks in the Democratic Republic of the Congo (overall 11% positivity rate of IgG antibodies to Zaire Ebola virus) and Southwestern Uganda [75,76].…”

Section: Discussionmentioning

confidence: 99%

Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples

et al. 2020

View full text Add to dashboard Cite

Surveillance of highly pathogenic viruses circulating in both human and animal populations is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the burden of disease by serological assay could be used as an early warning system for imminent outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the multitude of highly pathogenic viruses necessitates the need to identify specific antibodies against several targets from both humans as well as from potential reservoir animals such as bats. In order to address this, we have developed a broadly reactive multiplex microsphere immunoassay (MMIA) for the detection of antibodies against several highly pathogenic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each respective NP was shown by testing sera from humans and non-human primates with known infection status. The usefulness of our assay for serosurveillance was shown by determining the immune response against the NP antigens in a panel of 129 human serum samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera from the German blood bank. We found good agreement between our MMIA and commercial or in-house reference methods by ELISA or IIFT with statistically significant higher PLOS NEGLECTED TROPICAL DISEASES

show abstract

“…Another interesting consideration from a diagnostic perspective is the existence of IgG seropositive asymptomatic case contacts and other healthy blood donors who have no history of severe Ebolalike disease. A study of case contacts in Sierra Leone reported Ebola IgG seroprevalence at 11% [24]. In a recent study from Boende Health Zone in the DRC (site of the 2014 EVD outbreak) a range of serological tests were used to screen 565 health workers (not restricted to case contacts), among whom 234 (41.4%) were sero-reactive to at least one EBOV protein [25].…”

Section: Ebola Transmission Dynamicsmentioning

confidence: 99%